factor X

(redirected from Factor Xa)
Also found in: Dictionary, Thesaurus, Medical, Acronyms.
Related to Factor Xa: factor IIa

factor X

[′fak·tər ′ten]
(biochemistry)
References in periodicals archive ?
20] While factor Xa inhibitors do affect the PT, this is unpredictable and unreliable as a quantitative marker of the degree of anticoagulation.
Factor Xa inhibitor concentrations of the supplemented plasma samples were determined using anti-Xa assay (Berichrom Heparin, Siemens).
Although some special coagulation tests may be applied to estimate the extent of thrombin or factor Xa inhibition, lack of standardized monitoring tests is still an important limitation for therapy with new anticoagulants especially in acute situations where measuring the anticoagulant effect is desirable (30).
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
It inhibits the activation of thrombin, factor Xa and other clotting factors within the body's clotting pathway.
The study is designed to demonstrate the safety of PRT4445 and its ability to reverse the anticoagulation activity of ELIQUIS and other Factor Xa inhibitors, including betrixaban, Portola's Phase 3 oral Factor Xa inhibitor.
Pradaxa's first-to-market status may give it an initial advantage over factor Xa inhibitors, but brands that achieve incremental improvements over Pradaxa may ultimately achieve greater success given the serious and costly clinical events associated with atrial fibrillation (stroke and systemic embolic events) and the risk of major bleeding with warfarin," continued Mr.
Portola Pharmaceuticals and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Merck plans to return to Portola all rights for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation (SPAF).
Daiichi Sankyo has submitted a New Drug Application to the FDA for edoxaban, its investigational direct factor Xa inhibitor.
The submission is supported by data from the pivotal, global Phase 3 ROCKET AF (Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial.
for assessing Portola's investigational Factor Xa inhibitor reversal agent, andexanet alfa (PRT4445), with the oral Factor Xa inhibitor Eliquis (apixaban).
ATLANTA -- Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor.